Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

Posted: May 9, 2023 at 12:10 am

First Wave of Investigational RAS(ON) Inhibitors – RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) – progressing on plan

See more here:
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

Related Posts